Insilico Medicine Announces The Nomination Of Two Preclinical Candidates For PHD2, 12 Months After Program Initiation

Published by
The Street

By PR Newswire NEW YORK and SHANGHAI, Jan. 5, 2022 /PRNewswire/ — Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidates (PCC) for ISM012-077 and ISM012-042 for the treatment of anemia of chronic kidney disease (CKD) and inflammatory bowel disease (IBD), respectively. ISM012-077 and ISM012-042 are small-molecule prolyl hydroxylase domain 2 (PHD2) inhibitors with novel scaffolds and distinct binding modes…

Read More